Skyler B Johnson1, James B Yu2,3. 1. Department of Therapeutic Radiology, Yale School of Medicine, HRT 138, 333 Cedar St, New Haven, CT, 06520, USA. 2. Department of Therapeutic Radiology, Yale School of Medicine, HRT 138, 333 Cedar St, New Haven, CT, 06520, USA. james.b.yu@yale.edu. 3. Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT, USA. james.b.yu@yale.edu.
Abstract
PURPOSE OF REVIEW: Here, we will review and summarize the current status and emerging data supporting the use of trimodality therapy as an alternative to cystectomy for patients with muscle-invasive bladder cancer. RECENT FINDINGS: There are no randomized-controlled data comparing radical cystectomy with bladder preserving trimodality therapy available for comparison. However, observational data suggests acceptable bladder preservation and functional outcomes in patients receiving bladder preserving trimodality therapy as well as similar oncologic outcomes in select patients compared to radical cystectomy. Future trials are focusing on new techniques and novel therapeutics in patients with bladder cancer. Bladder preserving trimodality therapy results in satisfactory quality of life and comparable disease outcomes for select patients with muscle-invasive urothelial carcinoma of the bladder compared to cystectomy.
PURPOSE OF REVIEW: Here, we will review and summarize the current status and emerging data supporting the use of trimodality therapy as an alternative to cystectomy for patients with muscle-invasive bladder cancer. RECENT FINDINGS: There are no randomized-controlled data comparing radical cystectomy with bladder preserving trimodality therapy available for comparison. However, observational data suggests acceptable bladder preservation and functional outcomes in patients receiving bladder preserving trimodality therapy as well as similar oncologic outcomes in select patients compared to radical cystectomy. Future trials are focusing on new techniques and novel therapeutics in patients with bladder cancer. Bladder preserving trimodality therapy results in satisfactory quality of life and comparable disease outcomes for select patients with muscle-invasive urothelial carcinoma of the bladder compared to cystectomy.
Authors: Ross E Krasnow; Michael Drumm; Hannah J Roberts; Andrzej Niemierko; Chin-Lee Wu; Shulin Wu; Jing Zhang; Niall M Heney; Matthew F Wszolek; Michael L Blute; Adam S Feldman; Richard J Lee; Anthony L Zietman; William U Shipley; Jason A Efstathiou Journal: Eur Urol Date: 2016-12-28 Impact factor: 20.096
Authors: M H Hussain; T R Glass; J Forman; W Sakr; D C Smith; M Al-Sarraf; J Jones; S P Balcerzak; E D Crawford; H B Grossman Journal: J Urol Date: 2001-01 Impact factor: 7.450
Authors: Alan Horwich; David Dearnaley; Robert Huddart; John Graham; Eric Bessell; Malcolm Mason; Judith Bliss Journal: Radiother Oncol Date: 2004-11-25 Impact factor: 6.280
Authors: J Dunst; R Sauer; K M Schrott; R Kühn; C Wittekind; A Altendorf-Hofmann Journal: Int J Radiat Oncol Biol Phys Date: 1994-09-30 Impact factor: 7.038
Authors: Guillaume Ploussard; Shahrokh F Shariat; Alice Dragomir; Luis A Kluth; Evanguelos Xylinas; Alexandra Masson-Lecomte; Malte Rieken; Michael Rink; Kazumasa Matsumoto; Eiji Kikuchi; Tobias Klatte; Stephen A Boorjian; Yair Lotan; Florian Roghmann; Adrian S Fairey; Yves Fradet; Peter C Black; Ricardo Rendon; Jonathan Izawa; Wassim Kassouf Journal: Eur Urol Date: 2013-10-09 Impact factor: 20.096
Authors: Robert A Huddart; Emma Hall; Syed A Hussain; Peter Jenkins; Christine Rawlings; Jean Tremlett; Malcolm Crundwell; Fawzi A Adab; Denise Sheehan; Isabel Syndikus; Carey Hendron; Rebecca Lewis; Rachel Waters; Nicholas D James Journal: Int J Radiat Oncol Biol Phys Date: 2013-10-01 Impact factor: 7.038
Authors: Dalia O Mohamed; Mona M Sayed; Islam F Abdelkawi; Mahmoud H Elshoieby; Salah M Khallaf; Lamia M Khallaf; Doaa M Fouad Journal: Curr Urol Date: 2021-03-29